Difference between revisions of "Diaz-Padilla I, et al. Gynecol. Oncol. (2015) cited as Ref 587 in DOI: 10.1038/s41392-020-0110-5 (Q9850)"
Jump to navigation
Jump to search
(Added link to [sliswiki]: Diaz-Padilla I, et al. Gynecol. Oncol. (2015) cited as Ref 587 in DOI: 10.1038/s41392-020-0110-5, #quickstatements; #temporary_batch_1589988087154) |
(Created claim: Page(s) (P105): 216-222, #quickstatements; #temporary_batch_1590074839150) |
||||||||||||||
| (7 intermediate revisions by the same user not shown) | |||||||||||||||
| Property / First Author string | |||||||||||||||
| + | Diaz-Padilla I | ||||||||||||||
| Property / First Author string: Diaz-Padilla I / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / DOI Identifier | |||||||||||||||
| + | |||||||||||||||
| Property / DOI Identifier: 10.1016/j.ygyno.2015.03.005 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / PubMed ID | |||||||||||||||
| + | |||||||||||||||
| Property / PubMed ID: 25769658 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Publication Date | |||||||||||||||
| + | 2015
| ||||||||||||||
| Property / Publication Date: 2015 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Published In Name String | |||||||||||||||
| + | Gynecol. Oncol. | ||||||||||||||
| Property / Published In Name String: Gynecol. Oncol. / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Volume | |||||||||||||||
| + | 137 | ||||||||||||||
| Property / Volume: 137 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / title | |||||||||||||||
| + | A phase II study of single-agent RO4929097 a gamma-secretase inhibitor of Notch signaling in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret Chicago and California phase II consortia (English) | ||||||||||||||
| Property / title: A phase II study of single-agent RO4929097 a gamma-secretase inhibitor of Notch signaling in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret Chicago and California phase II consortia (English) / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
| Property / Page(s) | |||||||||||||||
| + | 216-222 | ||||||||||||||
| Property / Page(s): 216-222 / rank | |||||||||||||||
| + | Normal rank | ||||||||||||||
Latest revision as of 15:46, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Diaz-Padilla I, et al. Gynecol. Oncol. (2015) cited as Ref 587 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Diaz-Padilla I
0 references
2015
0 references
Gynecol. Oncol.
0 references
137
0 references
A phase II study of single-agent RO4929097 a gamma-secretase inhibitor of Notch signaling in patients with recurrent platinum-resistant epithelial ovarian cancer: a study of the Princess Margaret Chicago and California phase II consortia (English)
0 references
216-222
0 references
